Metric Finance
LearnFAQ
LearnFAQ

Learn / ATTO

NASDAQ: ATTO

Attovia Therapeutics (ATTO) stock, explained like you're 5

Attovia Therapeutics trades on the Nasdaq under the ticker ATTO. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 740 million dollars.

Ticker
ATTO
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Small cap, about 740 million dollars

Is Attovia Therapeutics a small, medium or large cap company?

No. Attovia Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 740 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Attovia Therapeutics makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves ATTO stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Short Interest Report for September (MarketBeat)
  • symbol__ Stock Quote Price and Forecast (CNN)
  • Attovia Therapeutics (ATTO) amends CFO option grant report with no ownership changes. (Stock Titan)
  • Upcoming and recent IPOs IPOs calendar (Yahoo Finance Australia)
  • Goldman Sachs backed Attovia eyes $731.5 million valuation in upsized US IPO (Reuters)

Follow ATTO in your daily brief

Each trading day at 5 PM ET we post what happened to Attovia Therapeutics and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow ATTO

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Attovia Therapeutics stock

What does Attovia Therapeutics do?

Attovia Therapeutics trades on the Nasdaq under the ticker ATTO. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 740 million dollars.

What is the ticker symbol for Attovia Therapeutics?

Attovia Therapeutics trades under the ticker ATTO on the Nasdaq.

What is Attovia Therapeutics's market cap?

Attovia Therapeutics is a small cap stock with a market cap of about 740 million dollars.

How does Attovia Therapeutics make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves ATTO stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow ATTO stock every day?

Add ATTO to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow ATTO daily

A free brief on Attovia Therapeutics and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare ATTO: ATTO vs ARGX, ATTO vs RVMD, ATTO vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed